Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Could AstraZeneca Shares Be On The Way To New Highs?

By Investing.com (Tezcan Gecgil/Investing.com )Stock MarketsSep 16, 2020 10:57
uk.investing.com/analysis/could-astrazeneca-shares-be-on-the-way-to-new-highs-200446778
Could AstraZeneca Shares Be On The Way To New Highs?
By Investing.com (Tezcan Gecgil/Investing.com )   |  Sep 16, 2020 10:57
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

The COVID-19 pandemic has created several equity market winners, including pharma giant AstraZeneca (LON:AZN) (NYSE:AZN). The company, along with its partner Oxford University, is developing a vaccine targeting SARS-CoV-2, the virus that causes COVID-19.

Year-to-date, AZN stock is up around 11% on investor optimism about the company's drug pipeline, including the potential vaccine. In late July, the UK-listed shares hit an all-time high 10,120p. They now change hands around 8,605p. U.S.-listed shares, which hit an all-time high at $64.94 during the same period, currently hover at $55.

AstraZeneca 1-Year Chart.
AstraZeneca 1-Year Chart.

As of Sept. 15, the number of globally reported COVID-19 infections has surpassed 29 million. The outbreak has already killed close to 1 million people worldwide. Therefore, governments and populations around the globe are ready to welcome the news that a vaccine or drug is ready for use.

In late July, AstraZeneca released robust Q2 results that beat expectations. Its current treatments as well as its channel of drugs for major ailments include cardiovascular disease, diabetes, gastrointestinal problems, infection, inflammation, oncology, renal and respiratory conditions. Investors now wonder if they should buy into the company, which is one of the frontrunners in the hot race to develop a vaccine against the novel coronavirus. Let's take a closer look.

AstraZeneca At Top Of The FTSE

In early 2020, before the pandemic became a part of our daily lives, oil major Royal Dutch Shell (LON:RDSb) (NYSE:RDSa) had the largest market capitalization on the FTSE 100, the UK's leading stock index.

By early spring, the leadership position had moved to AstraZeneca—clearly a sign of the times. Late-stage trials are under way not only in the UK, but also in Brazil, South Africa, and the U.S. Then, earlier this month, the company announced that it was pausing the clinical trials of its coronavirus vaccine candidate, AZD1222. The reason was a potential side effect.

However, earlier this week, the UK's Medicines Health Regulatory Authority gave the go-ahead to restart the studies. Between the two announcements, AZN stock has had a choppy ride.

On the FTSE, AZN shares are followed by another healthcare and vaccine leader GlaxoSmithKline (LON:GSK) (NYSE:GSK). In July, GSK and CureVac (NASDAQ:CVAC) announced strategic messenger ribonucleic acid (mRNA) technology collaboration. Messenger RNA transmits instructions to the body to produce proteins against a given disease. However, unlike AZN stock, year-to-date, GSK shares are down around 15%.

As a result of the recent increase in AZN stock, its valuation has become rich. Its forward P/E, P/S and P/B ratios stand at 22.68, 5.49 and 11.54, respectively. By comparison, those metrics for GSK stock are 12.94, 2.20 and 5.64.

Long-term investors who also pay attention to short-term technical analysis and charts may be interested to know that AZN stock is currently overbought. Although shares can stay overbought for a long time, a pullback in broader markets or the pharma sector would likely affect AstraZeneca, too.

Who Else Is In The Race?

Governments, citizens and investors around the world are watching a wide range of biotechs and pharma companies that have completed various steps in developing a treatment that may finally receive approval.

In addition to AstraZeneca, GlaxoSmithKline and CureVac, there is a range of companies working on a vaccine or another type of drug in the fight against the novel coronavirus. This list includes:

  • Amgen (NASDAQ:AMGN)
  • Biontech (NASDAQ:BNTX)
  • Gilead (NASDAQ:GILD)
  • Ibio (NYSE:IBIO)
  • Inovio Pharmaceuticals (NASDAQ:INO)
  • Moderna (NASDAQ:MRNA)
  • Novavax (NASDAQ:NVAX)
  • Pfizer (NYSE:PFE)
  • Sanofi (NASDAQ:SNY), and
  • Sorrento Therapeutics (NASDAQ:SRNE)

Shares in companies involved in the efforts to develop a cure against COVID-19 have become heavily driven by new headlines. As firms release news updates, investors either hit the "buy" or the "sell" button. In the coming weeks, any one of them could become a winner in the eyes of the public and investors.

Bottom Line

Vaccine development for COVID-19 is proceeding at full pelt while companies push to finalize clinical trials to develop a cure for the coronavirus. As one of the most-respected names in the biopharma space, AstraZeneca deserves investors’ attention for its vaccine candidate as well as its regular pharma operations and additional drugs it has in the pipeline.

However, we find AZN shares pricey at these levels. Potential investors may regard a decline of 5%-7% as an entry point into the stock. In the case of positive news regarding its clinical trial, AZN may easily hit a new all-time high. Long-term shareholders would also be entitled to dividends. Current yield stands at 2.59%.

Investors may also want to do further due diligence on GSK stock whose dividend yield is 5.28%. We’d consider buying the dips.

On a final note, we believe Pfizer and Moderna may also be among the first companies to make successful announcements. Investors may want to keep those shares on their radar screen, too.

Could AstraZeneca Shares Be On The Way To New Highs?
 

Related Articles

Could AstraZeneca Shares Be On The Way To New Highs?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email